연구성과로 돌아가기

2023 연구성과별 연구자 정보 (1761 / 2675)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) De Toni, Enrico N. De Toni, EN 11 C-6496-2008 De Toni, Enrico
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Tam, Vincent C. Tam, VC 12
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Mody, Kabir Mody, K 13
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Gong, Jun Gong, J 14
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Mccoy, Carrie L. Mccoy, CL 15
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Gupta, Charu Gupta, C 16
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Makowsky, Mallory Makowsky, M 17
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Negro, Alejandra Negro, A 18
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) Abou-Alfa, Ghassan K. Abou-Alfa, GK 19
Outcomes of Angular Stable Locking System in Femoral Diaphyseal Fractures of Elderly Patients: A Multicenter Comparative Study Hwang, Kyu Tae Hwang, KT 1 Hanyang Univ Hosp, Dept Orthopaed Surg, Seoul, South Korea R-7249-2016 Hwang, Kyu 0000-0003-2477-7888 Hwang, Kyu Tae kcpark@hanyang.ac.kr;
Outcomes of Angular Stable Locking System in Femoral Diaphyseal Fractures of Elderly Patients: A Multicenter Comparative Study Kook, Incheol Kook, I 2 Hanyang Univ Hosp, Dept Orthopaed Surg, Seoul, South Korea 0000-0001-8691-5495 Kook, Incheol kcpark@hanyang.ac.kr;
Outcomes of Angular Stable Locking System in Femoral Diaphyseal Fractures of Elderly Patients: A Multicenter Comparative Study Lee, Jae-Ho Lee, JH 3 Hanyang Univ, Dept Orthopaed Surg, Guri Hosp, Guri, South Korea kcpark@hanyang.ac.kr;
Outcomes of Angular Stable Locking System in Femoral Diaphyseal Fractures of Elderly Patients: A Multicenter Comparative Study Oh, Chang-Wug Oh, CW 4 Kyungpook Natl Univ Hosp, Dept Orthopaed Surg, Daegu, South Korea AAO-4602-2021 Oh, Chang-Wug 0000-0002-1224-0787 Oh, Chang-Wug kcpark@hanyang.ac.kr;
Outcomes of Angular Stable Locking System in Femoral Diaphyseal Fractures of Elderly Patients: A Multicenter Comparative Study Sohn, Oog-Jin Sohn, OJ 5 Yeungnam Univ, Dept Orthopaed Surg, Med Ctr, Daegu, South Korea 0000-0002-9123-5694 Shon, Oog-jin kcpark@hanyang.ac.kr;
Outcomes of Angular Stable Locking System in Femoral Diaphyseal Fractures of Elderly Patients: A Multicenter Comparative Study Kim, Ji Wan Kim, JW 6 Univ Ulsan, Asan Med Ctr, Dept Orthopaed Surg, Coll Med, Seoul, South Korea 0000-0002-3524-8706 Kim, Ji Wan kcpark@hanyang.ac.kr;
페이지 이동: